Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)

"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Michael DeMarco, PhD

by Michael DeMarco, PhD

Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review - PubMed
Our findings are consistent with 2 prior reports that have highlighted the use of naltrexone in KUDs. The 2 previous case reports indicated that naltrexone at the dosage of 50 mg/day successfully helped the patients to achieve abstinence. Studies have shown that naltrexone reduces the antidepressant …
PubMedRishi Verma

(2025):"Our findings are consistent with 2 prior reports that have highlighted the use of naltrexone in KUDs. The 2 previous case reports indicated that naltrexone at the dosage of 50 mg/day successfully helped the patients to achieve abstinence. Studies have shown that naltrexone reduces the antidepressant effects of ketamine in treatment-resistant depression, indicating an overlap between the opioid system and ketamine's NMDA receptor activity."

Important to note that while ketamine can be used as a medicine in substance use disorder, people can sometimes become dependent with misuse, which may be addressed by naltrexone.

More like this

Spotlight: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring (in mice)

"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"

Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)

"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."

Spotlight: The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health (Du, et al, 2025)

"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."

Spotlight: The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry (Soylemez, et al, 2025)

"These compounds have been shown to enable access to unconscious cognitive and emotional content, facilitate emotional release, and induce a temporary dissolution of ego boundaries—processes that may underpin significant and enduring therapeutic outcomes."

Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)

" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "

Spotlight: Key competencies for psychedelic treatment in real-world mental health care settings (Wolff, et al, 2025)

"To accommodate mainstream adoption of these treatments, the competencies framework we present respects the distinctive contextual and cultural sensitivities of psychedelic care while remaining anchored in established psychotherapeutic, medical, and scientific paradigms."
Mastodon Mastodon